Zhenhuan Cao, Yali Liu, Lina Ma, Junfeng Lu, Yi Jin, Shan Ren, Zhimin He, Chengli Shen, Xinyue Chen – 13 April 2017 – Hepatitis B surface antigen (HBsAg) clearance represents a clinical cure, although the clearance rate is extremely low. The aim of this study was to evaluate the feasibility and safety profiles of pegylated‐interferon α‐2a (PEG‐IFNα‐2a) as a therapeutic option for inactive HBsAg carriers. There were 144 inactive HBsAg carriers enrolled and divided into a therapeutic group (102 subjects) and a control group (42 subjects).

Paolo Magistri, Giuseppe Tarantino, Roberto Ballarin, Andrea Coratti, Fabrizio Di Benedetto – 13 April 2017

Bruno Sangro, Diego Martínez‐Urbistondo, Lourens Bester, Jose I. Bilbao, Douglas M. Coldwell, Patrick Flamen, Andrew Kennedy, Jens Ricke, Ricky A. Sharma – 13 April 2017 – Selective internal radiation therapy (or radioembolization) by intra‐arterial injection of radioactive yttrium‐90‐loaded microspheres is increasingly used for the treatment of patients with liver metastases or primary liver cancer. The high‐dose beta‐radiation penetrates an average of only 2.5 mm from the source, thus limiting its effects to the site of delivery.

Po‐Da Chen, Yao‐Ming Wu – 13 April 2017

Yujie Li, Yongfeng Song, Meng Zhao, Yanjing Guo, Chunxiao Yu, Wenbin Chen, Shanshan Shao, Chao Xu, Xinli Zhou, Lifang Zhao, Zhenhai Zhang, Tao Bo, Yu Xia, Christopher G. Proud, Xuemin Wang, Li Wang, Jiajun Zhao, Ling Gao – 10 April 2017 – Cholesterol synthesis is regulated by the transcription factor sterol regulatory element binding protein 2 (SREBP‐2) and its target gene 3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase (HMGCR), which is the rate‐limiting enzyme in cholesterol synthesis.

Atsushi Ono, Nicolas Goossens, Richard S. Finn, Warren N. Schmidt, Swan N. Thung, Gene Y. Im, Yujin Hoshida, on behalf of Precision Liver Cancer Prevention Consortium – 8 April 2017

Atsushi Ono, Nicolas Goossens, Richard S. Finn, Warren N. Schmidt, Swan N. Thung, Gene Y. Im, Yujin Hoshida, on behalf of Precision Liver Cancer Prevention Consortium – 8 April 2017

Mark R. Deneau, Wael El‐Matary, Pamela L. Valentino, Reham Abdou, Khaled Alqoaer, Mansi Amin, Achiya Z. Amir, Marcus Auth, Fateh Bazerbachi, Annemarie Broderick, Albert Chan, Jillian Cotter, Sylvia Doan, Mounif El‐Youssef, Federica Ferrari, Katryn N. Furuya, Madeleine Gottrand, Frederic Gottrand, Nitika Gupta, Matjaz Homan, Binita M.

Mark R. Deneau, Wael El‐Matary, Pamela L. Valentino, Reham Abdou, Khaled Alqoaer, Mansi Amin, Achiya Z. Amir, Marcus Auth, Fateh Bazerbachi, Annemarie Broderick, Albert Chan, Jillian Cotter, Sylvia Doan, Mounif El‐Youssef, Federica Ferrari, Katryn N. Furuya, Madeleine Gottrand, Frederic Gottrand, Nitika Gupta, Matjaz Homan, Binita M.

Shanshan Liu, Yu Sun, Ming Jiang, Yangkai Li, Ye Tian, Weili Xue, Ninghe Ding, Yue Sun, Cheng Cheng, Jianshuang Li, Xiaoping Miao, Xinran Liu, Ling Zheng, Kun Huang – 7 April 2017 – Up‐regulated glyceraldehyde‐3‐phosphate dehydrogenase (GAPDH) is observed in multiple cancers with unclear mechanism. Using GAPDH transgenic mouse and a mouse model of diethylnitrosamine‐induced hepatocellular carcinoma (HCC), here we show that GAPDH overexpression aggravated tumor development by activating cell proliferation and inflammation.